Vertex Pharmaceuticals Incorporated (VRTX)
Data as of September 4, 2026 · Biotechnology
Stockbruh grade: Strong 5/5 metrics rated Sunny
What does Vertex Pharmaceuticals Incorporated do?
Vertex Pharmaceuticals Incorporated, based in Boston, is a biotech company dedicated to developing and selling therapies for cystic fibrosis. They offer products like SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, targeting specific mutations. With an impressive pipeline of innovative treatments in development, such as VX-864 for AAT deficiency and CTX001 for severe SCD and TDT, Vertex Pharmaceuticals is committed to improving the lives of patients. 🧬💊.
Key Numbers
| Metric | Rating | What it means |
|---|
| Returns (5Y) | ☀️ Strong | 5-year price performance |
| Profitability | ☀️ Strong | Net margin & return on equity |
| Growth | ☀️ Strong | Revenue & earnings trend |
| Earnings | ☀️ Strong | EPS vs analyst expectations |
| Cash & Debt | ☀️ Strong | Balance sheet strength |
| Price | $556.75 | Market Cap | — |
| Exchange | NASDAQ Global Select | | |
Plain-English Analysis
What's it worth?
Based on 5-year performance trends, Vertex Pharmaceuticals Incorporated has historically delivered strong returns. Sign up free for full valuation analysis including P/E, DCF estimates, and Stockbruh's plain-English take on whether this stock looks cheap or expensive right now.
How the business works
Vertex Pharmaceuticals Incorporated, based in Boston, is a biotech company dedicated to developing and selling therapies for cystic fibrosis. They offer products like SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, targeting specific mutations. Sign up free for competitor and revenue breakdown ↗
Are they building the future?
Revenue and earnings are trending upward — Vertex Pharmaceuticals Incorporated appears to be growing. Sign up free for the full growth analysis including year-over-year comparisons and R&D investment data.
What's ahead?
Recent earnings have been strong, meeting or beating analyst expectations. Sign up free for earnings history, EPS trends, and what analysts are forecasting next.